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Background: In the CHAMPION PHOENIX trial, compared with clopidogrel, can-
grelor was shown to signiﬁcantly reduce the primary composite endpoint of death,
myocardial infarction (MI), ischemia driven revascularization (IDR), or stent throm-
bosis (ST) at 48 hours, as well as the secondary endpoint of ST. Protocol ST included
intraprocedural ST (IPST) and Academic Research Consortium (ARC) deﬁned ST. To
examine the robustness of the effect of cangrelor on ischemic events, we performed
sequential sensitivity analyses of the primary composite endpoint by excluding IPST
and applying increasingly stringent criteria of MI.
Methods: A total of 10,942 patients undergoing PCI for elective, urgent, or emergent
indications were randomized to intravenous cangrelor bolus and infusion or to clo-
pidogrel loading in the catheterization laboratory. Sensitivity analyses were performed
examining progressively more restrictive deﬁnitions of MI and ST. Ischemic end-
points were adjudicated in a blinded fashion.
Results: The Table lists sensitivity analyses of various composite efﬁcacy endpoints at
48 hours in the modiﬁed intent-to-treat (mITT) population. There was a consistent risk
reduction with cangrelor irrespective of the exact composite outcome examined.
Speciﬁcally for MI, even when all biomarker deﬁned MI were excluded, the treatment
effect of cangrelor remained signiﬁcant (death, MI only with symptoms or ischemic
ECG changes, IDR, or ARC-ST; odds ratio 0.66, p¼0.003).Composite
Efﬁcacy
Endpoints
Cangrelor
(N¼5472)
Clopidogrel
(N¼5470)
Odds Ratio and
95% CI p-value
Death/MI/
IDR/ST
(primary
endpoint)
257/5470 (4.7) 322/5469 (5.9) 0.79 (0.67, 0.93) 0.006
Death/MI/
IDR/ARC-ST
230/5470 (4.2) 286/5469 (5.2) 0.80 (0.67, 0.95) 0.01
Death/QMI/
IDR/ARC-ST
49/5470 (0.9) 64/5469 (1.2) 0.76 (0.53, 1.11) 0.16
Death/
MI10xULN/
IDR/ARC-ST
77/5470 (1.4) 111/5469 (2.0) 0.69 (0.51, 0.92) 0.01
Death/
MI10xULN
with normal
baseline/
IDR/ARC-ST
75/5470 (1.4) 108/5469 (2.0) 0.69 (0.51, 0.93) 0.01
Death/
MI10xULN
or with
symptom or
ECGD/IDR/
ARC-ST
106/5470 (1.9) 161/5469 (2.9) 0.65 (0.51, 0.83) 0.0007
Death/MI
with
symptom or
ECGD/IDR/
ARC-ST
86/5470 (1.6) 130/5469 (2.4) 0.66 (0.50, 0.86) 0.003Conclusions: Compared with clopidogrel, cangrelor reduces important ischemic
events, even using the most restrictive deﬁnitions of MI and ST.B142 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT AbstraTCT-483
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Background: Increasing HbA1c portends an adverse cardiovascular prognosis.
However, the association between glycemic control, platelet reactivity, and outcomes
after PCI with drug-eluting stents (DES) is unknown.
Methods: In the prospective multicenter ADAPT-DES registry, HbA1c levels were
measured in 1,145/8,582 enrolled patients. We stratiﬁed patients by HbA1c < 6.5%
(n¼547, 47.8%), 6.5-8.5% (n¼422, 36.8%) and >8.5% (n¼176, 15.4%). Platelet
reactivity was assessed post-PCI with the VerifyNow system after aspirin and clopi-
dogrel loading. High platelet reactivity (HPR) on clopidogrel was deﬁned as P2Y12
reaction units (PRU) >208.
Results: Patients with HbA1c >8.5% were younger, more likely female and non-
Caucasian, had a higher BMI, and more insulin-treated diabetes and acute coronary
syndromes. Hypertension, coronary artery disease, heart failure and renal insufﬁ-
ciency were less present when HbA1c was < 6.5%. HPR and stent thrombosis (ST)
increased with greater HbA1c (Figure). Clinically relevant bleeding was greatest in
the intermediate HbA1c group (8.0% vs. 12.8% vs. 8.5%, P¼0.04). After adjust-
ment, HbA1c no longer correlated with HPR (OR¼1.02 [0.97, 1.06], p¼0.49).
However, in a propensity-adjusted model, HbA1c remained associated with ST
(HR¼3.91 [1.36, 11.22], p¼0.01) but not bleeding (HR¼0.98 [0.66, 1.47], p¼0.94)
at 2 years.Conclusions: In this large-scale study, the association between HbA1c and HPR was
driven by comorbidities associated with poor glycemic control. Nonetheless, greater
HbA1c independently predicted ST after PCI, warranting efforts to improve glycemic
control after DES in diabetic patients.cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
